Bicara Therapeutics Q1 net loss $36.8M; cash $462M; ASCO data update planned

Bicara Therapeutics Inc.

2025-Q1 EPS reported -$0.68

Cash and cash equivalents of $462.1M as of March 31, 2025, expected to fund operations into H1 2029.
Net loss of $36.8M in Q1 2025, versus $12.5M in Q1 2024; R&D expenses rose to $34.3M.
Updated Phase 1/1b data for ficerafusp alfa in 1L R/M HNSCC to be presented at ASCO 2025 (June 1).
cSCC monotherapy expansion cohort showed ORR of 30.4% and median PFS of 7.0 months at AACR.
Pivotal Phase 2/3 FORTIFI-HN01 trial enrolling; additional expansion cohorts ongoing or planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.